Title: Remimazolam alleviates hepatic ischemia-reperfusion injury by activating FOXO1/3
signaling
Version: 2 Date: 19 Feb 2025
Reviewer's report:
In this study, a liver ischemia-reperfusion injury model was established through animal
experiments, and a cell hypoxia-reperfusion injury model was established by subjecting cells to
hypoxia and then reoxygenation. It was explored that remimazolam alleviates liver ischemia-
reperfusion injury by activating the FOXO1/3 signaling pathway. The overall design of the full
text is reasonable, and the experimental results can effectively support the research objectives.
However, there are still some related issues:
1.When establishing the animal model, the mice were not placed on a thermostatic plate, which
shows a lack of awareness of animal protection in terms of ethics. At the same time, it may have
an impact on the data.
2.The model of ischemia-reperfusion injury was established by clamping the left and middle
hepatic arteries. However, it is not described in the later part which specimens were taken from
the left lobe and the middle lobe of the liver. Please provide a detailed description, author.
3.The time for establishing liver ischemia in mice was 60 minutes, and the reperfusion time was
6 hours. What is the basis for determining these two time periods? Were any preliminary animal
experiments conducted to determine them? Please provide a detailed description.
4.In the RMZL group, the mice received an intraperitoneal injection of RMZL at a dose of 20 mg/
kg. Where does the basis for determining this concentration come from? Were any concentration
gradient preliminary experiments conducted? Please provide a detailed description.
5.In the experimental grouping, the RMZL group has no comparative significance throughout
the entire experimental process, and there is no need to set up this group.
Title: Remimazolam alleviates hepatic ischemia-reperfusion injury by activating FOXO1/3
signaling
Version: 2 Date: 19 Feb 2025
Reviewer's report:
In this study, a liver ischemia-reperfusion injury model was established through animal
experiments, and a cell hypoxia-reperfusion injury model was established by subjecting cells to
hypoxia and then reoxygenation. It was explored that remimazolam alleviates liver ischemia-
reperfusion injury by activating the FOXO1/3 signaling pathway. The overall design of the full
text is reasonable, and the experimental results can effectively support the research objectives.
However, there are still some related issues:
1.When establishing the animal model, the mice were not placed on a thermostatic plate, which
shows a lack of awareness of animal protection in terms of ethics. At the same time, it may have
an impact on the data.
2.The model of ischemia-reperfusion injury was established by clamping the left and middle
hepatic arteries. However, it is not described in the later part which specimens were taken from
the left lobe and the middle lobe of the liver. Please provide a detailed description, author.
3.The time for establishing liver ischemia in mice was 60 minutes, and the reperfusion time was
6 hours. What is the basis for determining these two time periods? Were any preliminary animal
experiments conducted to determine them? Please provide a detailed description.
4.In the RMZL group, the mice received an intraperitoneal injection of RMZL at a dose of 20 mg/
kg. Where does the basis for determining this concentration come from? Were any concentration
gradient preliminary experiments conducted? Please provide a detailed description.
5.In the experimental grouping, the RMZL group has no comparative significance throughout
the entire experimental process, and there is no need to set up this group.
Please review this paper.
user
Title: Remimazolam alleviates hepatic ischemia-reperfusion injury by activating FOXO1/3
signaling
Version: 2 Date: 19 Feb 2025
Reviewer's report:
In this study, a liver ischemia-reperfusion injury model was established through animal
experiments, and a cell hypoxia-reperfusion injury model was established by subjecting cells to
hypoxia and then reoxygenation. It was explored that remimazolam alleviates liver ischemia-
reperfusion injury by activating the FOXO1/3 signaling pathway. The overall design of the full
text is reasonable, and the experimental results can effectively support the research objectives.
However, there are still some related issues:
1.When establishing the animal model, the mice were not placed on a thermostatic plate, which
shows a lack of awareness of animal protection in terms of ethics. At the same time, it may have
an impact on the data.
2.The model of ischemia-reperfusion injury was established by clamping the left and middle
hepatic arteries. However, it is not described in the later part which specimens were taken from
the left lobe and the middle lobe of the liver. Please provide a detailed description, author.
3.The time for establishing liver ischemia in mice was 60 minutes, and the reperfusion time was
6 hours. What is the basis for determining these two time periods? Were any preliminary animal
experiments conducted to determine them? Please provide a detailed description.
4.In the RMZL group, the mice received an intraperitoneal injection of RMZL at a dose of 20 mg/
kg. Where does the basis for determining this concentration come from? Were any concentration
gradient preliminary experiments conducted? Please provide a detailed description.
5.In the experimental grouping, the RMZL group has no comparative significance throughout
the entire experimental process, and there is no need to set up this group.
assistant